The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Relapse after HSCT 2021 | Treating patients relapsed after auto-SCT
Sergio Giralt, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the management of patients who relapse after autologous stem cell transplant (auto-SCT), in particular discussing the role of second transplantation in multiple myeloma and chimeric antigen receptor T-cell (CAR-T) therapy in lymphoma. Dr Giralt also comments on ways in which CAR-T therapies can be made more widely available, highlighting the role of shared care models. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Disclosures
Sergio Giralt, MD, PhD, discloses links to Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ and Actinuum.
